UPDATED: Big Pharma grounds employees: GSK, Bristol, Roche, Sanofi and more limit travel due to coronavirus

travel
Several drugmakers say they are restricting employee travel as global the COVID-19 outbreak continues to gain steam. (Pexels/C. Cagnin)

Biopharma companies are hunkering down as the COVID-19 epidemic breaks out worldwide.

In a FiercePharma survey of biopharma companies late last month, most drugmakers said they were simply limiting travel to hard-hit countries such as China, South Korea and Italy. Now, as more cases pop up across the U.S., Europe and Asia, their tone has shifted.

GlaxoSmithKline has “instructed all employees to postpone non-critical international business travel until further notice,” a spokesman said. Bristol Myers Squibb started restricting on business travel and put the kibosh on workplace and company meetings until the end of March. And BMS' limits don't just apply to employees and contractors, but to partners, suppliers and vendors, too, a spokeswoman said.

On-Demand Webinar

Leveraging A Medical Record-Enriched Patient Dataset for COVID-19 Research

You are invited to join a webinar that will explore the ways researchers can leverage this enriched dataset for important COVID-19 research. Sign up today for this informative webinar to learn how you can leverage one of the only medical record reviews solely using real-world data from hospitalized COVID-19 patients.

Boehringer Ingelheim, for its part, is restricting travel throughout Europe, where the case count has picked up in the last several days. The German drugmaker has also put China, Hong Kong, Macau, Taiwan, southeast Asia, South Korea, Japan and Iran off-limits. 

"We expect employees to reschedule business meetings that require traveling or organize them virtually in those areas," a spokesperson said, adding that the restrictions aren't entirely new. They're a more detailed version of a previous policy limiting travel in affected areas. 

Swiss drug giant Roche is asking employees to "postpone all travel to China, including Hong Kong and Macau, until further notice," and "limit business travel to and from Korea, Japan, Singapore, Iran and Italy to the absolute business-critical activity only." Any employee returning from one of those areas must work from home for at least 14 days upon their return, Roche says.

Amgen is suspending international business travel until April 17 and strengthening cleaning routines and visitor screening at all of its locations. The company also won't travel to medical conferences until April 17.

Takeda is promoting telework and and canceling international and domestic travel that is not in a "private vehicle." Eli Lilly is also asking U.S. employees to work from home and limiting U.S. travel.

"We continue to monitor this dynamic situation locally, regionally and nationally, and will adjust as necessary," Lilly's statement said.

Last week, the drugmakers who responded to FiercePharma's inquiries mostly said they are monitoring the situation and restricting travel to and from China. GSK also restricted travel to Italy and South Korea at the time. 

RELATED: AbbVie, GSK, Sanofi and more limit employee travel as coronavirus threatens business 

In a new statement, Sanofi said it’s requesting employees and contractors to avoid travel in China, Hong Kong, Macau, South Korea, Iran and seven regions in Italy. They’re asked to “keep all the travels to business essential only,” with some exceptions, such as to return home. Sanofi has created an “internal crisis committee” and still prohibits travel to Wuhan and throughout China’s Hubei province.  

Mylan is limiting international travel and prohibiting travel to and from China, Hong Kong, Iran, Italy, Japan and South Korea.

"We are asking that all business travel is minimized and alternatives to travel and in-person meetings are considered," a spokeswoman said.

AstraZeneca is limiting travel, encouraging certain employees to work from home and taking "appropriate measures to ensure continuity and mitigate any impact to our research and development programmes." Novartis has updated its own travel policies, as well.

The travel restrictions and limitations are designed to help contain the novel coronavirus, which has spread to 85 countries, infecting about 100,000 people worldwide. The virus has caused more than 3,300 deaths.

Among those infected are three Biogen employees—two from Europe and one from outside of Massachusetts—who traveled to a management meeting in Boston last week. At the meeting, several attendees had flu-like symptoms, according to a company statement. Several tested positive for flu, while three have confirmed COVID-19 infections.

In response, Biogen has instructed all of the meeting attendees to work from home for at least two weeks and is restricting employee travel through the end of March. Aside from those who attended the meeting, any employee should stay home if they don’t feel well and contact healthcare providers as necessary, Biogen says. 

RELATED: Biogen cracks down on travel after 3 execs test positive for coronavirus 

Biogen isn't alone. Seattle-area employees for Amazon and Microsoft have tested positive for COVID-19, as has a contractor for Facebook. Tech companies in Seattle are asking employees to work from home, and some have shut down certain offices.

Amid the threat, two prominent cancer centers—the Dana-Farber Cancer Institute and MD Anderson—are restricting business travel. And the Healthcare Information and Management Systems Society canceled its annual conference in Orlando for the first time in more than 50 years. Prominent medical conferences say they are monitoring the situation, but haven’t made a decision to cancel. 

Editor's note: Kyle Blankenship contributed reporting.

Suggested Articles

Life sciences companies have pivoted quickly during COVID-19 - Syneos Health® is supporting more than 80 active COVID-19 projects, including vaccines.

New York's Covaxx has signed on with three South American nations to provide 140 million doses of its early-stage COVID-19 vaccine.

To get the COVID-19 vaccine out quickly, Pfizer has been running rehearsals at distribution sites, creating "growing confidence," U.S. officials said.